KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Goodwill Goodwill & Intangibles Intangibles Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Evolent Health (EVH) Notes Payables (2023 - 2025)

Evolent Health has reported Notes Payables over the past 3 years, most recently at $5.1 million for Q3 2025.

For Q3 2025, Notes Payables changed N/A year-over-year to $5.1 million; the TTM value through Sep 2025 reached $5.1 million, changed N/A, while the annual FY2024 figure was $171.5 million, N/A changed from the prior year.
Notes Payables for Q3 2025 was $5.1 million at Evolent Health, down from $172.1 million in the prior quarter.
Over five years, Notes Payables peaked at $172.1 million in Q2 2025 and troughed at $991000.0 in Q3 2023.
A 3-year average of $104.3 million and a median of $171.5 million in 2024 define the central range for Notes Payables.